Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16476028 | 1.00 | EZH2 (0.90) | EZH2CYP2D6CYP2C19 | |
| SCHEMBL17136268 | 0.96 | EZH2 (0.90) | EZH2CYP2D6CYP2C19 | |
| SCHEMBL15700442 | 0.96 | EZH2 (0.90) | EZH2CYP2D6CYP2C19 | |
| SCHEMBL15647641 | 0.96 | EZH2 (0.90) | EZH2CYP2D6CYP2C19 | |
| SCHEMBL15647852 | 0.95 | EZH2 (1.00) | EZH2CYP2D6CYP2C19 | |
| SCHEMBL16476033 | 0.95 | EZH2 (1.00) | EZH2CYP2D6CYP2C19 | |
| SCHEMBL15647850 | 0.95 | EZH2 (1.00) | EZH2CYP2D6CYP2C19 | |
| SCHEMBL17136207 | 0.93 | EZH2 (0.96) | EZH2CYP2D6CYP2C19 | |
| SCHEMBL15700495 | 0.93 | EZH2 (0.96) | EZH2CYP2D6CYP2C19 | |
| SCHEMBL17136202 | 0.93 | EZH2 (0.96) | EZH2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024331-A1 | METHOD FOR TREATING CANCER | Epizyme, Inc. | 2024-01-25 | — | — | US | disclosed |
| US-11786533-B2 | Use of EZH2 inhibitors for treating cancer | Epizyme, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230181549-A1 | USE OF EZH2 INHIBITORS FOR TREATING CANCER | Epizyme, Inc. | 2023-06-15 | — | — | US | disclosed |
| US-11642349-B2 | Method for treating cancer | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642346-B2 | Combination therapy for treating cancer | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642347-B2 | EZH2 inhibitors for treating lymphoma | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20180133224-A1 | METHOD FOR TREATING CANCER | Epizyme, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-20180071300-A1 | METHOD OF TREATING CANCER | Epizyme, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-9889138-B2 | Method for treating cancer | Epizyme, Inc. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170305889-A1 | METHODS OF TREATING CANCER | Epizyme, Inc. | 2017-10-26 | — | — | US | disclosed |
| US-9688665-B2 | Methods of treating cancer | Epizyme, Inc. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9532992-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160346293-A1 | METHOD FOR TREATING CANCER | Epizyme, Inc. | 2016-12-01 | — | — | US | disclosed |
| US-20160228447-A1 | METHOD OF TREATING CANCER | Epizyme, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-20150352119-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-9089575-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150174136-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2015-06-25 | — | — | US | disclosed |
| US-9006242-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140107122-A1 | Substituted Benzene Compounds | Epizyme, Inc. | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11642349-B2 | Method for treating cancer | EZH2, BMI1, DOT1L | EZH2 1/4885CYP2D6 4483/4885CYP2C19 4682/4885 |
| US-11642347-B2 | EZH2 inhibitors for treating lymphoma | EZH2, DOT1L, BMI1 | EZH2 1/4885CYP2D6 4028/4885CYP2C19 4010/4885 |
| US-11642346-B2 | Combination therapy for treating cancer | EZH2, RET, KMT2A | EZH2 1/4885CYP2D6 4718/4885CYP2C19 4406/4885 |
| US-20150284370-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | EZH2 2519/4885CYP2D6 25/4885CYP2C19 140/4885 |
| US-20140107122-A1 | Substituted Benzene Compounds | CYP1B1, TP53, VHL | EZH2 2519/4885CYP2D6 25/4885CYP2C19 140/4885 |
| US-20240024331-A1 | METHOD FOR TREATING CANCER | EZH2, BMI1, DOT1L | EZH2 1/4885CYP2D6 4483/4885CYP2C19 4682/4885 |
| US-20150174136-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | EZH2 2519/4885CYP2D6 25/4885CYP2C19 140/4885 |
| US-20230181549-A1 | USE OF EZH2 INHIBITORS FOR TREATING CANCER | EZH2, DOT1L, EZH1 | EZH2 1/4885CYP2D6 3696/4885CYP2C19 3945/4885 |
| US-20180133224-A1 | METHOD FOR TREATING CANCER | EZH2, BMI1, EZH1 | EZH2 1/4885CYP2D6 4447/4885CYP2C19 4435/4885 |
| US-20160346293-A1 | METHOD FOR TREATING CANCER | EZH2, BMI1, EZH1 | EZH2 1/4885CYP2D6 4447/4885CYP2C19 4435/4885 |
| US-20170305889-A1 | METHODS OF TREATING CANCER | EZH2, BMI1, DOT1L | EZH2 1/4885CYP2D6 4795/4885CYP2C19 4568/4885 |
| US-11786533-B2 | Use of EZH2 inhibitors for treating cancer | EZH2, DOT1L, EZH1 | EZH2 1/4885CYP2D6 3699/4885CYP2C19 3962/4885 |
| US-20150352119-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | EZH2 2519/4885CYP2D6 25/4885CYP2C19 140/4885 |
| US-20160228447-A1 | METHOD OF TREATING CANCER | EZH2, BMI1, EZH1 | EZH2 1/4885CYP2D6 4562/4885CYP2C19 4235/4885 |
| US-20180071300-A1 | METHOD OF TREATING CANCER | EZH2, BMI1, EZH1 | EZH2 1/4885CYP2D6 4622/4885CYP2C19 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.